10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424
5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560
About DepoFoam®
Our proprietary, extended-release drug delivery technology DepoFoam® is a multivesicular liposomal platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time from 1 to 30 days.
DepoFoam has been used in two FDA-approved commercial products, including
DepoCyt(e)® (cytarabine liposome injection), as well as the company's newest FDA-approved product, EXPAREL® (bupivacaine liposome injectable suspension).
The DepoFoam technology provides several advantages over competitive technologies, including:
| Technical Attributes | Regulatory Attributes | Commercial Attributes |
|---|---|---|
| Convenience: A ready-to-use product; can be used with patient friendly narrow gauge needles and pen systems |
Multiple regulatory precedents: Regulatory authorities are familiar with our DepoFoam technology; two products, including DepoCyt(e) have been approved in the United States and Europe |
Commercial marketing experience: DepoFoam-based products have been sold for more than a decade, providing for an established safety and efficacy database |
| Administration into privileged sites: DepoFoam products are approved for epidural and intrathecal administration |
Shortened development timeline: DepoFoam does not alter the native molecule, enabling the filing of a 505(b)(2) application |
Proven manufacturing capabilities: DepoFoam-based products continue to be made in our cGMP facilities |
| Aseptic manufacturing and filling: Enables use with proteins, peptides, nucleic acids, vaccines and small molecules |
- Proprietary proven delivery platform
- Two products: worldwide registrations and supply
- Manufactured and developed at Pacira's cGMP facilities for more than 15 years
- Ongoing technology enhancement programs
